Dimethyl fumarate regulates histone deacetylase expression in astrocytes

Journal of Neuroimmunology

Volumn 263, Issue 1-2, 2013, Pages 13-19

  Kalinin, Sergey ^a   Polak, Paul E ^a   Lin, Shao Xia ^a   Braun, David ^a   Guizzetti, Marina ^a,b   Zhang, Xiaolu ^a,b   Rubinstein, Israel ^b,c   Feinstein, Douglas L ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Jesse Brown Veterans Affairs Medical Center   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Astrocyte; Histone deacetylase; Multiple sclerosis; Nrf2

Indexed keywords

FUMARIC ACID DIMETHYL ESTER; HEME OXYGENASE 1; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 2A.1; HISTONE DEACETYLASE 3A.3; HISTONE DEACETYLASE 4; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LYSINE; MESSENGER RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; CELL STIMULATION; CONTROLLED STUDY; DNA BINDING; DRUG ACTIVITY; ENZYME REGULATION; FEMALE; GENE TARGETING; HISTONE ACETYLATION; INCUBATION TIME; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; RAT;

EID: 84884819095     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.07.007     Document Type: Article

References (77)

1. Ago T., Liu T., Zhai P., Chen W., Li H., Molkentin J.D., Vatner S.F., Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 2008, 133:978-993.
2. Ahmed K.A., Sawa T., Akaike T. Protein cysteine S-guanylation and electrophilic signal transduction by endogenous nitro-nucleotides. Amino Acids 2011, 41:123-130.
3. Aspenström P. Formin-binding proteins: modulators of formin-dependent actin polymerization. Biochim. Biophys. Acta 2010, 1803:174-182.
4. Baltan S., Murphy S.P., Danilov C.A., Bachleda A., Morrison R.S. Histone deacetylase inhibitors preserve white matter structure and function during ischemia by conserving ATP and reducing excitotoxicity. J. Neurosci. 2011, 31:3990-3999.
5. Bianchi R., Kastrisianaki E., Giambanco I., Donato R. S100B protein stimulates microglia migration via RAGE-dependent up-regulation of chemokine expression and release. J. Biol. Chem. 2011, 286:7214-7226.
6. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5:769-784.
7. Bovenschen H.J., Langewouters A.M., van de Kerkhof P.C. Dimethylfumarate for psoriasis: pronounced effects on lesional T-cell subsets, epidermal proliferation and differentiation, but not on natural killer T cells in immunohistochemical study. Am. J. Clin. Dermatol. 2010, 11:343-350.
8. Brandenburg L.O., Kipp M., Lucius R., Pufe T., Wruck C.J. Sulforaphane suppresses LPS-induced inflammation in primary rat microglia. Inflamm. Res. 2010, 59:443-450.
9. Buck C.R., Jurynec M.J., Gupta D.K., Law A.K., Bilger J., Wallace D.C., McKeon R.J. Increased adenine nucleotide translocator 1 in reactive astrocytes facilitates glutamate transport. Exp. Neurol. 2003, 181:149-158.
10. Camelo S., Iglesias A.H., Hwang D., Due B., Ryu H., Smith K., Gray S.G., Imitola J., Duran G., Assaf B., Langley B., Khoury S.J., Stephanopoulos G., De G.U., Ratan R.R., Ferrante R.J., Dangond F. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:10-21.
11. Chen S.H., Wu H.M., Ossola B., Schendzielorz N., Wilson B.C., Chu C.H., Chen S.L., Wang Q., Zhang D., Qian L., Li X., Hong J.S., Lu R.B. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage. Br. J. Pharmacol. 2012, 165:494-505.
12. Colussi C., Mozzetta C., Gurtner A., Illi B., Rosati J., Straino S., Ragone G., Pescatori M., Zaccagnini G., Antonini A., Minetti G., Martelli F., Piaggio G., Gallinari P., Steinkuhler C., Clementi E., Dell'Aversana C., Altucci L., Mai A., Capogrossi M.C., Puri P.L., Gaetano C. HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:19183-19187.
13. Cross S.A., Cook D.R., Chi A.W., Vance P.J., Kolson L.L., Wong B.J., Jordan-Sciutto K.L., Kolson D.L. Dimethyl fumarate, an immune modulator and inducer of the antioxidant response, suppresses HIV replication and macrophage-mediated neurotoxicity: a novel candidate for HIV neuroprotection. J. Immunol. 2011, 187:5015-5025.
14. Danilov C.A., Chandrasekaran K., Racz J., Soane L., Zielke C., Fiskum G. Sulforaphane protects astrocytes against oxidative stress and delayed death caused by oxygen and glucose deprivation. Glia 2009, 57:645-656.
15. Jong De, Bezemer A.C., Zomerdijk T.P., van de Pouw-Kraan T., Ottenhoff T.H., Nibbering P.H. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur. J. Immunol. 1996, 26:2067-2074.
16. Dethlefsen L.A., Lehman C.M., Biaglow J.E., Peck V.M. Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells. Radiat. Res. 1988, 114:215-224.
17. Dietz K.C., Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol. Res. 2010, 62:11-17.
18. Doyle K., Fitzpatrick F.A. Redox signaling, alkylation (carbonylation) of conserved cysteines inactivates class I histone deacetylases 1, 2, and 3 and antagonizes their transcriptional repressor function. J. Biol. Chem. 2010, 285:17417-17424.
19. d'Ydewalle C., Bogaert E., Van Den B.L. HDAC6 at the Intersection of Neuroprotection and Neurodegeneration. Traffic 2012, 13:771-779.
20. Ellrichmann G., Petrasch-Parwez E., Lee D.H., Reick C., Arning L., Saft C., Gold R., Linker R.A. Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease. PLoS One 2011, 6:e16172.
21. Faraco G., Pittelli M., Cavone L., Fossati S., Porcu M., Mascagni P., Fossati G., Moroni F., Chiarugi A. Histone deacetylase (HDAC) inhibitors reduce the glial inflammatory response in vitro and in vivo. Neurobiol. Dis. 2009, 36:269-279.
22. Faraco G., Cavone L., Chiarugi A. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol. Med. 2011, 17:442-447.
23. Fox R. The New England Journal of Medicine publishes pivotal data demonstrating efficacy and safety of oral BG-12 (dimethyl fumarate) in multiple sclerosis. Can. J. Neurosci. Nurs. 2012, 34:7-11.
24. Fox R.J., Miller D.H., Phillips J.T., Hutchinson M., Havrdova E., Kita M., Yang M., Raghupathi K., Novas M., Sweetser M.T., Viglietta V., Dawson K.T. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 2012, 367:1087-1097.
25. Frycak P., Zdrahal Z., Ulrichova J., Wiegrebe W., Lemr K. Evidence of covalent interaction of fumaric acid esters with sulfhydryl groups in peptides. J. Mass Spectrom. 2005, 40:1309-1318.
26. Galea E., Feinstein D.L., Reis D.J. Induction of calcium-independent nitric oxide synthase activity in primary rat glial cultures. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10945-10949.
27. Ge Z., Da Y., Xue Z., Zhang K., Zhuang H., Peng M., Li Y., Li W., Simard A., Hao J., Yao Z., Zhang R. Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis. Exp. Neurol. 2013, 241:56-66.
28. Ghoreschi K., Bruck J., Kellerer C., Deng C., Peng H., Rothfuss O., Hussain R.Z., Gocke A.R., Respa A., Glocova I., Valtcheva N., Alexander E., Feil S., Feil R., Schulze-Osthoff K., Rupec R.A., Lovett-Racke A.E., Dringen R., Racke M.K., Rocken M. Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells. J. Exp. Med. 2011, 208:2291-2303.
29. Giudice A., Arra C., Turco M.C. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods Mol. Biol. 2010, 647:37-74.
30. Goebbels S., Oltrogge J.H., Kemper R., Heilmann I., Bormuth I., Wolfer S., Wichert S.P., Mobius W., Liu X., Lappe-Siefke C., Rossner M.J., Groszer M., Suter U., Frahm J., Boretius S., Nave K.A. Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination. J. Neurosci. 2010, 30:8953-8964.
31. Gold R., Linker R.A., Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin. Immunol. 2012, 142:44-48.
32. Graber D.J., Hickey W.F., Stommel E.W., Harris B.T. Anti-inflammatory efficacy of dexamethasone and Nrf2 activators in the CNS using brain slices as a model of acute injury. J. Neuroimmune Pharmacol. 2012, 7:266-278.
33. Gray S.G. Epigenetic treatment of neurological disease. Epigenomics 2011, 3:431-450.
34. Gray S.G., Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006, 1:67-75.
35. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannenbaum S.R. Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal. Biochem. 1982, 126:131-138.
36. Haggarty S.J., Tsai L.H. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol. Learn. Mem. 2011, 96:41-52.
37. Hashioka S., Klegeris A., McGeer P.L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-gamma. J. Neuroinflammation 2012, 9:113.
38. Hoxtermann S., Nuchel C., Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998, 196:223-230.
39. Jacob C., Lebrun-Julien F., Suter U. How histone deacetylases control myelination. Mol. Neurobiol. 2011, 44:303-312.
40. Jain A.K., Bloom D.A., Jaiswal A.K. Nuclear import and export signals in control of Nrf2. J. Biol. Chem. 2005, 280:29158-29168.
41. Kappos L., Gold R., Miller D.H., Macmanus D.G., Havrdova E., Limmroth V., Polman C.H., Schmierer K., Yousry T.A., Yang M., Eraksoy M., Meluzinova E., Rektor I., Dawson K.T., Sandrock A.W., O'Neill G.N. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008, 372:1463-1472.
42. Kassam S., Goenaga-Infante H., Maharaj L., Hiley C.T., Juliger S., Joel S.P. Methylseleninic acid inhibits HDAC activity in diffuse large B-cell lymphoma cell lines. Cancer Chemother. Pharmacol. 2011, 68:815-821.
43. Kawai Y., Garduno L., Theodore M., Yang J., Arinze I.J. Acetylation-deacetylation of the transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) regulates its transcriptional activity and nucleocytoplasmic localization. J. Biol. Chem. 2011, 286:7629-7640.
44. Keller A., Nesvizhskii A.I., Kolker E., Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal. Chem. 2002, 74:5383-5392.
45. Keum Y.S. Regulation of the Keap1/Nrf2 system by chemopreventive sulforaphane: implications of posttranslational modifications. Ann. N. Y. Acad. Sci. 2011, 1229:184-189.
46. Kim S.K., Yang H., Pascual J.M., De Vivo D.C. Valproic acid enhances glucose transport in the cultured brain astrocytes of glucose transporter 1 heterozygous mice. J. Child Neurol. 2013, 28:70-76.
47. Lehmann J.C., Listopad J.J., Rentzsch C.U., Igney F.H., von B.A., Hennekes H.H., Asadullah K., Docke W.D. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J. Invest. Dermatol. 2007, 127:835-845.
48. Lin S.X., Lisi L., Dello R.C., Polak P.E., Sharp A., Weinberg G., Kalinin S., Feinstein D.L. The anti-inflammatory effects of dimethyl fumarate in astrocytes involve glutathione and haem oxygenase-1. ASN Neuro 2011, 3.
49. Linker R.A., Lee D.H., Ryan S., Van Dam A.M., Conrad R., Bista P., Zeng W., Hronowsky X., Buko A., Chollate S., Ellrichmann G., Bruck W., Dawson K., Goelz S., Wiese S., Scannevin R.H., Lukashev M., Gold R. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134:678-692.
50. Lyssiotis C.A., Walker J., Wu C., Kondo T., Schultz P.G., Wu X. Inhibition of histone deacetylase activity induces developmental plasticity in oligodendrocyte precursor cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14982-14987.
51. Magesh S., Chen Y., Hu L. Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents. Med. Res. Rev. 2012, 32:687-726.
52. Myzak M.C., Karplus P.A., Chung F.L., Dashwood R.H. A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res. 2004, 64:5767-5774.
53. Nesvizhskii A.I., Keller A., Kolker E., Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 2003, 75:4646-4658.
54. Niture S.K., Khatri R., Jaiswal A.K. Regulation of Nrf2 - An update. Free Radic. Biol. Med. 2013, (pii: S0891-5849(13)00061-0). 10.1016/j.freeradbiomed.2013.02.008.
55. Nott A., Watson P.M., Robinson J.D., Crepaldi L., Riccio A. S-nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons. Nature 2008, 455:411-415.
56. Oh C.J., Kim J.Y., Choi Y.K., Kim H.J., Jeong J.Y., Bae K.H., Park K.G., Lee I.K. Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling. PLoS One 2012, 7:e45870.
57. Pastore A., Piemonte F. S-Glutathionylation signaling in cell biology: progress and prospects. Eur. J. Pharm. Sci. 2012, 46:279-292.
58. Rostami-Yazdi M., Clement B., Mrowietz U. Pharmacokinetics of anti-psoriatic fumaric acid esters in psoriasis patients. Arch. Dermatol. Res. 2010, 302:531-538.
59. Scannevin R.H., Chollate S., Jung M.Y., Shackett M., Patel H., Bista P., Zeng W., Ryan S., Yamamoto M., Lukashev M., Rhodes K.J. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. 2012, 341:274-284.
60. Schellenberg G.D., Montine T.J. The genetics and neuropathology of Alzheimer's disease. Acta Neuropathol. 2012, 124:305-323.
61. Schmidt M.M., Dringen R. Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione. Neurochem. Int. 2010, 57:460-467.
62. Schmidt T.J., Ak M., Mrowietz U. Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-L-cysteine-preparation of S-substituted thiosuccinic acid esters. Bioorg. Med. Chem. 2007, 15:333-342.
63. Schwedkendiek W. Treatment of psoriasis vulgaris. Med. Monatsschr. 1959, 13:103-104.
64. Seidel P., Goulet S., Hostettler K., Tamm M., Roth M. DMF inhibits PDGF-BB induced airway smooth muscle cell proliferation through induction of heme-oxygenase-1. Respir. Res. 2010, 11:145.
65. Shein N.A., Shohami E. Histone deacetylase inhibitors as therapeutic agents for acute central nervous system injuries. Mol. Med. 2011, 17:448-456.
66. Spencer S.R., Wilczak C.A., Talalay P. Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res. 1990, 50:7871-7875.
67. Suh H.S., Choi S., Khattar P., Choi N., Lee S.C. Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes. J. Neuroimmune Pharmacol. 2010, 5:521-532.
68. Sun Z., Chin Y.E., Zhang D.D. Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. Mol. Cell. Biol. 2009, 29:2658-2672.
69. Suuronen T., Huuskonen J., Pihlaja R., Kyrylenko S., Salminen A. Regulation of microglial inflammatory response by histone deacetylase inhibitors. J. Neurochem. 2003, 87:407-416.
70. Treumer F., Zhu K., Glaser R., Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J. Invest. Dermatol. 2003, 121:1383-1388.
71. Voisin P.J., Pardue S., Morrison-Bogorad M. Developmental characterization of thymosin beta 4 and beta 10 expression in enriched neuronal cultures from rat cerebella. J. Neurochem. 1995, 64:109-120.
72. Wang B., Zhu X., Kim Y., Li J., Huang S., Saleem S., Li R.C., Xu Y., Dore S., Cao W. Histone deacetylase inhibition activates transcription factor Nrf2 and protects against cerebral ischemic damage. Free Radic. Biol. Med. 2011, 52:928-936.
73. Wierinckx A., Breve J., Mercier D., Schultzberg M., Drukarch B., Van Dam A.M. Detoxication enzyme inducers modify cytokine production in rat mixed glial cells. J. Neuroimmunol. 2005, 166:132-143.
74. Wilms H., Sievers J., Rickert U., Rostami-Yazdi M., Mrowietz U., Lucius R. Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1beta, TNF-alpha and IL-6 in an in-vitro model of brain inflammation. J. Neuroinflammation 2010, 7:30.
75. Xu K., Dai X.L., Huang H.C., Jiang Z.F. Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid. Med. Cell. Longev. 2011, 2011:143269.
76. Yang H., Cui G.B., Jiao X.Y., Wang J., Ju G., You S.W. Thymosin-beta4 attenuates ethanol-induced neurotoxicity in cultured cerebral cortical astrocytes by inhibiting apoptosis. Cell. Mol. Neurobiol. 2010, 30:149-160.
77. Yu Y., Casaccia P., Lu Q.R. Shaping the oligodendrocyte identity by epigenetic control. Epigenetics 2010, 5:124-128.